NCT03614546 is a NA clinical trial of SBRT in Primary Hepatocellular Carcinoma, sponsored by The Third Xiangya Hospital of Central South University.

Who is sponsoring NCT03614546?

NCT03614546 is sponsored by The Third Xiangya Hospital of Central South University.

What drugs are being tested in NCT03614546?

Interventions in NCT03614546: SBRT, IMRT, Hepatectomy, TACE.

What condition does NCT03614546 study?

NCT03614546 studies Primary Hepatocellular Carcinoma.

Is NCT03614546 still recruiting?

NCT03614546 is currently status unknown. Last updated 23 January 2019.

Last reviewed 2019-01-23 · How we verify

NCT03614546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma

Status unknown NA Last updated 23 January 2019

What this trial tests

NA trial testing SBRT in Primary Hepatocellular Carcinoma in 200 participants. Status unknown.

Timeline

10 October 2018

Primary endpoint
30 July 2020

30 July 2021

Quick facts

Lead sponsor	The Third Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	10 October 2018
Primary completion	30 July 2020
Estimated completion	30 July 2021
Sites	1 location across China

Drugs / interventions tested

SBRT — full drug profile →
IMRT
Hepatectomy
TACE

Conditions studied

Primary Hepatocellular Carcinoma — all drugs for Primary Hepatocellular Carcinoma →

Sponsor

The Third Xiangya Hospital of Central South University

Who can join

Adults 18 to 80, any sex, with Primary Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The subjects of primary hepatocellular carcinoma diagnosed pathologically or clinically will be grouped according to the size, location, number and function of the liver, and respectively received Intensity-modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Transarterial chemoembolization (TACE) or surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SBRT

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
NCT07410234 — Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity · Phase 2 · not yet recruiting

Other The Third Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07353307 — A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia Afte · Phase 3 · recruiting
NCT07123207 — Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Dis · NA · recruiting
NCT07034664 — IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study · recruiting
NCT07093294 — Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter · recruiting
NCT07039097 — A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resectio · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03614546 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Xiangya Hospital of Central South University
Last refreshed: 23 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03614546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing